HyperArc Registry Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05270707

Enrollment

968

Registered

2022-03-08

Start date

2022-03-31

Completion date

2025-03-31

Last updated

2025-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Metastases, CNS Disorder, Intracranial, CNS Neoplasm

Keywords

Stereotactic Radiosurgery

Brief summary

The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.

Detailed description

A significant percentage of newly diagnosed cancer patients will develop brain metastases. For many of these patients, stereotactic radiosurgery (SRS) is recommended as a primary treatment option. Concerns about complexity, patient safety, cost, and human resources can make SRS challenging. HyperArc radiotherapy addresses these challenges by introducing key technology and workflow elements to streamline multi-leaf collimator-based, non-coplanar SRS. HyperArc is designed to deliver SRS treatments from the TrueBeam linear accelerator platform. The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.

Interventions

RADIATIONStereotactic radiosurgery

HyperArc is a radiotherapy treatment with a structured workflow to plan and deliver stereotactic radiosurgery (SRS).

Study design

Observational model

CASE_ONLY

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Received or scheduled to receive treatment using the HyperArc treatment method * Age of legal adult according to local law * Signed informed consent form, or, informed consent waived by the local ethics board/institutional review board

Exclusion criteria

* None, apart from not meeting Inclusion Criteria

Design outcomes

Primary

Measure	Time frame	Description
Survival	follow until death, on average approximately 2 years	Survival

Secondary

Measure	Time frame	Description
Local tumor control	follow until death, on average approximately 2 years	Response of treated tumors
HyperArc Patterns of Care	Limited to course of treatment: up to 4 weeks	Dosimetry information for clinically delivered HyperArc treatments

Countries

Australia, Belgium, Italy, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026